## WHAT IS CLAIMED IS:

A saponin derivative useful for inhibiting sialyltransferase,

which is the general formula (I) or the pharmaceutically acceptable salts

and esters thereof:

wherein

 $R_1$  is hydrogen,  $C_{1-8}$  alkyl,  $C_{2-6}$  alkynyl,  $C_{2-6}$  alkynyl, or  $C_{1-8}$  alkylhydroxy;

R<sub>2</sub> is hydrogen, C<sub>1-8</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, COOH, COOC<sub>1-8</sub>alkyl;

 $R_3$  is  $C_{1-8}$  alkylhydroxy, hydrogen,  $C_{1-8}$  alkyl,  $C_{2-6}$  alkenyl or  $C_{2-6}$ 

10

5

10

15

20

alkynyl;

R<sub>4</sub> is pentose or hexose residue or their derivatives; and m is 0, 1, 2 or 3.

- 2. The saponin derivative of Claim 1, wherein R<sub>1</sub> is CH<sub>2</sub>OH or CH<sub>3</sub>; R<sub>2</sub> is COOH or COOMe; R<sub>3</sub> is CH<sub>2</sub>OH or H; and R<sub>4</sub> is rhamnose or galactose.
- 3. The saponin derivative of Claim 1, wherein the saponin of formula (I) is selected from soyasaponin I, soyasaponin II, kaikasaponin III, soyasaponin V and soyasaponin I-Methyl.
- 4. The saponin derivative of Claim 1, which can be used in the treatment of the disease associated with sialyltransferase.
- 5. The saponin derivative of Claim 4, wherein the diseases is selected from inflammation, allergy, infection by pathogens, oncogenesis, cancer, metastasis and invasion.
- 6. The saponin derivative of Claim 5, wherein the disease is cancer, metastasis or invasion.
- 7. A sialyltransferase inhibitor agent, which comprises the saponin derivative as defined in claim 1.
- 8. The agent of Claim 7, wherein R<sub>1</sub> is CH<sub>2</sub>OH or CH<sub>3</sub>; R<sub>2</sub> is COOH or COOMe; R<sub>3</sub> is CH<sub>2</sub>OH or H; and R<sub>4</sub> is rhamnose or galactose.
  - 9. The agent of Claim 7, wherein the saponin of formula (I) is

5

10

selected from soyasaponin I, soyasaponin II, kaikasaponin III, soyasaponin V and soyasaponin I-Methyl.

- 10. A method of inhibiting sialyltransferase, which comprises using the saponin derivative as defined in claim 1.
- 11. A method of treating the conditions associated with the sialyltransferase, which comprises administration of a sialyltransferase inhibitor agent of the invention to a patient suffering from, or susceptible to, such a condition.
- 12. The method of claim 11, wherein the condition is selected from inflammation, allergy, infection by pathogens, oncogenesis, cancer, metastasis, and invasion caused by sialyltransferases.
- 13 The method of Claim 12, wherein the condition is selected from cancer, metastasis and invasion.